Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1380

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 5
Chunk 1380
---
 64,431 
  
    End
    of period 
    $3,769,510  
    $28,478 

    Supplemental
    disclosure of cash flow information: 

    Cash
    paid for interest 
    $147,776  
    $28,128 
  
    Cash
    paid for income taxes 
    $-  
    $- 

    Schedule
    of Non-Cash Investing and Financing Activities: 

    Convertible
    note issued as a settlement of a previously accrued liability 
    $-  
    $150,000 
  
    Restricted
    stock issued for forgiveness of salary 
    $10,000  
    $2,158,050 
  
    Stock
    options issued for forgiveness of salary 
    $50,000  
    $2,614,790 
  
    Note
    payable, related party assigned to Note payable 
    $266,667  
    $- 
  
    Stock
    issued for exercise of options in exchange for note payable, related parties 
    $-  
    $100,000 
  
    Discount
    on convertible note payable 
    $-  
    $60,000 
  
    Stock issued for conversion of notes 
    $636,866  

The
accompanying notes are an integral part of these financial statements

F-6

JUPITER
NEUROSCIENCES, INC.

NOTES
TO FINANCIAL STATEMENTS

December
31, 2024 and 2023

Note
1 – Organization and Description of Business

Jupiter
Neurosciences, Inc. (the “Company”) is a clinical stage research and development pharmaceutical company located in Jupiter,
Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily
targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare diseases.
We are primarily targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. In the larger disease areas, we are primarily
targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics,